tiprankstipranks
Trending News
More News >
3SBio, Inc. (HK:1530)
:1530
Advertisement

3SBio (1530) AI Stock Analysis

Compare
7 Followers

Top Page

HK:1530

3SBio

(OTC:1530)

Rating:69Neutral
Price Target:
HK$31.00
▲(1.97%Upside)
The overall stock score of 69 reflects 3SBio's solid financial performance and strong technical momentum. However, the high valuation and overbought technical indicators suggest caution. Financial performance is the most significant factor, supported by revenue growth and balance sheet stability, but investors should be mindful of valuation concerns.
Positive Factors
Product Performance
TPIAO's sales increased 20.4% YoY to RMB5.1bn, becoming the leading drug in China's thrombocytopenia treatment market, with stable pricing and increasing penetration.
Revenue Growth
3SBio delivered a strong performance with revenue increasing 16.5% YoY to RMB9.1bn, driven by the robust growth of TPIAO, Mandi and other products.
Strategic Expansion
3SBio has expanded its pipeline through strategic in-licensing, acquiring four key assets, including Paclitaxel Oral Solution which has received NMPA approval.
Negative Factors
Dividend Payout
3SBio has declared a final dividend of HK$0.25/shares, for a payout ratio of ~29%.

3SBio (1530) vs. iShares MSCI Hong Kong ETF (EWH)

3SBio Business Overview & Revenue Model

Company Description3SBio Inc. is a leading biopharmaceutical company in China, specializing in the research, development, manufacturing, and commercialization of biopharmaceutical products. The company primarily focuses on providing therapies in oncology, nephrology, and autoimmune diseases. It offers a range of products, including recombinant human erythropoietin, recombinant human thrombopoietin, and other biologics, catering to the growing healthcare needs in China and select international markets.
How the Company Makes Money3SBio generates revenue through the sale of its biopharmaceutical products, particularly in the areas of oncology, nephrology, and autoimmune diseases. The company's revenue streams are primarily derived from its proprietary drugs, which include a portfolio of biologics such as recombinant human erythropoietin and thrombopoietin. Additionally, 3SBio engages in strategic partnerships and collaborations with other pharmaceutical companies to expand its product offerings and market reach. The company also invests in research and development to innovate and introduce new therapeutic solutions, which contribute to its long-term revenue growth.

3SBio Financial Statement Overview

Summary
3SBio demonstrates robust financial health with strong revenue and profit growth, solid balance sheet stability, and effective cash management. However, cash flow consistency needs improvement due to fluctuating capital expenditures and investing cash flows.
Income Statement
85
Very Positive
3SBio shows a strong income statement with consistent revenue growth from 2019 to 2024. The gross profit margin is robust, indicating efficient cost management, and the net profit margin has improved significantly over the years, demonstrating enhanced profitability. The EBIT and EBITDA margins are healthy, showcasing strong operational performance.
Balance Sheet
78
Positive
The balance sheet reflects a solid equity base with a decreasing debt-to-equity ratio over the years, signaling improved financial stability. Return on Equity (ROE) is strong, indicating effective utilization of equity. The equity ratio indicates a sound proportion of assets funded by equity, although the increase in total liabilities in recent years suggests a need for cautious financial management.
Cash Flow
70
Positive
Cash flow from operations has been positive, reflecting good cash management and business operations. However, the free cash flow growth is inconsistent due to fluctuating capital expenditures and investing cash flows, which may pose a risk to liquidity. The operating cash flow to net income ratio indicates healthy cash conversion, but the absence of 2024 cash flow data limits full analysis.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue9.11B7.82B6.86B6.38B5.59B
Gross Profit7.83B6.64B5.67B5.28B4.52B
EBITDA2.93B2.53B2.75B2.26B1.59B
Net Income2.09B1.55B1.92B1.65B835.79M
Balance Sheet
Total Assets24.21B23.63B21.99B19.21B17.68B
Cash, Cash Equivalents and Short-Term Investments5.79B5.99B7.01B4.70B4.36B
Total Debt3.55B4.84B4.47B2.63B2.91B
Total Liabilities6.18B7.11B6.59B4.55B4.58B
Stockholders Equity15.44B14.03B12.96B12.23B10.69B
Cash Flow
Free Cash Flow2.24B1.38B1.21B432.57M363.09M
Operating Cash Flow3.20B2.08B2.18B1.58B1.34B
Investing Cash Flow-1.36B-1.35B-3.72B-1.29B-1.87B
Financing Cash Flow-2.25B-352.98M714.91M-481.12M1.55B

3SBio Technical Analysis

Technical Analysis Sentiment
Positive
Last Price30.40
Price Trends
50DMA
22.49
Positive
100DMA
16.62
Positive
200DMA
11.39
Positive
Market Momentum
MACD
2.31
Negative
RSI
69.13
Neutral
STOCH
67.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1530, the sentiment is Positive. The current price of 30.4 is above the 20-day moving average (MA) of 26.38, above the 50-day MA of 22.49, and above the 200-day MA of 11.39, indicating a bullish trend. The MACD of 2.31 indicates Negative momentum. The RSI at 69.13 is Neutral, neither overbought nor oversold. The STOCH value of 67.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1530.

3SBio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
HK$121.46B33.678.17%7.52%-1.92%
72
Outperform
HK$33.70B37.8831.65%4.23%47.71%
69
Neutral
HK$72.95B30.5314.19%0.03%14.36%33.22%
68
Neutral
HK$120.01B63.056.14%0.20%7.63%-24.23%
65
Neutral
¥355.44B11.10-2.99%2.49%11.76%-10.16%
61
Neutral
$149.75B-0.72%49.33%90.96%
59
Neutral
HK$37.94B-19.78%25.96%39.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1530
3SBio
30.40
24.29
397.55%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
62.90
40.45
180.18%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
25.30
13.84
120.77%
HK:1177
Sino Biopharmaceutical
6.71
3.96
143.73%
HK:2269
Wuxi Biologics (Cayman)
29.85
19.29
182.67%
HK:1801
Innovent Biologics
88.20
49.30
126.74%

3SBio Corporate Events

3SBio and Pfizer Finalize License Agreement and Share Subscription
Jul 24, 2025

3SBio, a biopharmaceutical company, has announced that its License Agreement with Pfizer for the PD-1/VEGF bispecific antibody (SSGJ-707) has come into effect, allowing Pfizer an exclusive option to develop and commercialize the product in China. Additionally, Pfizer has agreed to subscribe to new shares of 3SBio, representing a 1.28% stake post-issuance, at a discounted price, raising approximately HK$785.0 million for 3SBio.

The most recent analyst rating on (HK:1530) stock is a Hold with a HK$25.81 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

3SBio Inc. Announces AGM Results, Dividend Payment, and Committee Changes
Jun 25, 2025

3SBio Inc. announced the results of its Annual General Meeting (AGM) held on June 25, 2025, where all proposed resolutions were passed by poll. The company also declared a final dividend payment and announced changes to its Nomination Committee. These developments are likely to impact the company’s governance structure and shareholder returns, potentially strengthening its position in the biotechnology sector.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

3SBio Announces Board Roles and Functions
Jun 25, 2025

3SBio Inc., a company incorporated in the Cayman Islands, has announced the roles and functions of its board of directors and board committees. The announcement details the positions of executive, non-executive, and independent non-executive directors within the audit, nomination, and remuneration committees. This update is crucial for stakeholders to understand the governance structure and leadership dynamics within 3SBio, potentially impacting the company’s strategic direction and decision-making processes.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

3SBio Inc. Updates Nomination Committee Terms of Reference
Jun 25, 2025

3SBio Inc. has outlined the terms of reference for its Nomination Committee, which is responsible for identifying and recommending suitable candidates for the company’s board of directors. The committee, comprising a majority of independent non-executive directors, plays a crucial role in overseeing board performance evaluations and developing nomination guidelines, thereby impacting the company’s governance and strategic direction.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

3SBio Inc. Announces Annual General Meeting with Key Resolutions
May 26, 2025

3SBio Inc. has announced its upcoming annual general meeting scheduled for June 25, 2025, in Shenyang, China. Key agenda items include the adoption of the 2024 financial statements, re-election of directors, declaration of a final dividend, and re-appointment of auditors. The meeting will also address resolutions related to the issuance of additional shares, which could impact the company’s capital structure and shareholder value.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

3SBio Partners with Pfizer for Global Licensing of Oncology Antibody
May 19, 2025

3SBio, Inc. has entered into an exclusive licensing agreement with Pfizer for its PD-1/VEGF bispecific antibody, SSGJ-707, granting Pfizer rights to develop, manufacture, and commercialize the product worldwide, excluding mainland China. This agreement includes an upfront payment of $1.25 billion to 3SBio, with potential additional payments up to $4.8 billion, and positions 3SBio strategically in the global oncology market, enhancing its industry standing and providing significant financial benefits.

The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 15, 2025